Health advisors vote 13 for and10 against Molnupirivir for COVID-19 Patients. Issues with lack of evidence of efficacy against new variants and birth defects cause doubt.
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.
FDA Panel Just Barely Recommends…
Health advisors vote 13 for and10 against Molnupirivir for COVID-19 Patients. Issues with lack of evidence of efficacy against new variants and birth defects cause doubt.
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.